JP2009515827A - 治療薬 - Google Patents
治療薬 Download PDFInfo
- Publication number
- JP2009515827A JP2009515827A JP2008536134A JP2008536134A JP2009515827A JP 2009515827 A JP2009515827 A JP 2009515827A JP 2008536134 A JP2008536134 A JP 2008536134A JP 2008536134 A JP2008536134 A JP 2008536134A JP 2009515827 A JP2009515827 A JP 2009515827A
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- agent
- antibody
- polypeptide
- ramp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101710118454 Calcitonin gene-related peptide type 1 receptor Proteins 0.000 claims abstract description 67
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 52
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 45
- 238000000034 method Methods 0.000 claims abstract description 31
- 230000000694 effects Effects 0.000 claims abstract description 25
- 238000003556 assay Methods 0.000 claims abstract description 10
- 102000005962 receptors Human genes 0.000 claims abstract description 8
- 108020003175 receptors Proteins 0.000 claims abstract description 8
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 7
- 201000011510 cancer Diseases 0.000 claims abstract description 7
- 208000008589 Obesity Diseases 0.000 claims abstract description 3
- 235000020824 obesity Nutrition 0.000 claims abstract description 3
- 102000056906 Calcitonin Receptor-Like Human genes 0.000 claims abstract 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract 3
- 150000007523 nucleic acids Chemical class 0.000 claims description 132
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 128
- 108020004707 nucleic acids Proteins 0.000 claims description 99
- 102000039446 nucleic acids Human genes 0.000 claims description 99
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 96
- 229920001184 polypeptide Polymers 0.000 claims description 93
- 239000003795 chemical substances by application Substances 0.000 claims description 86
- 239000003814 drug Substances 0.000 claims description 81
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 63
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 60
- 229940079593 drug Drugs 0.000 claims description 45
- 239000012634 fragment Substances 0.000 claims description 33
- 125000000539 amino acid group Chemical group 0.000 claims description 26
- 230000027455 binding Effects 0.000 claims description 26
- 238000009739 binding Methods 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 23
- 101000584593 Homo sapiens Receptor activity-modifying protein 3 Proteins 0.000 claims description 17
- 239000003446 ligand Substances 0.000 claims description 16
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 15
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 15
- 238000004519 manufacturing process Methods 0.000 claims description 14
- 239000000427 antigen Substances 0.000 claims description 13
- 108091007433 antigens Proteins 0.000 claims description 13
- 102000036639 antigens Human genes 0.000 claims description 13
- 230000002068 genetic effect Effects 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 13
- 102000050294 human RAMP3 Human genes 0.000 claims description 12
- 210000004408 hybridoma Anatomy 0.000 claims description 12
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 239000000047 product Substances 0.000 claims description 10
- 239000013598 vector Substances 0.000 claims description 8
- 230000003993 interaction Effects 0.000 claims description 7
- 230000035755 proliferation Effects 0.000 claims description 7
- 238000012216 screening Methods 0.000 claims description 7
- 108091023037 Aptamer Proteins 0.000 claims description 6
- 239000011230 binding agent Substances 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 108020004459 Small interfering RNA Proteins 0.000 claims description 4
- 108020001507 fusion proteins Proteins 0.000 claims description 4
- 102000037865 fusion proteins Human genes 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 239000003550 marker Substances 0.000 claims description 4
- 239000004055 small Interfering RNA Substances 0.000 claims description 4
- 230000003053 immunization Effects 0.000 claims description 3
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 206010036030 Polyarthritis Diseases 0.000 claims description 2
- 239000000556 agonist Substances 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 230000000692 anti-sense effect Effects 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 206010003246 arthritis Diseases 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000003085 diluting agent Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000005764 inhibitory process Effects 0.000 claims description 2
- 210000004698 lymphocyte Anatomy 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 201000008482 osteoarthritis Diseases 0.000 claims description 2
- 201000008968 osteosarcoma Diseases 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 208000030428 polyarticular arthritis Diseases 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 150000001875 compounds Chemical class 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 208000013600 Diabetic vascular disease Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 101000934069 Homo sapiens Calpain-1 catalytic subunit Proteins 0.000 claims 1
- 101000793880 Homo sapiens Caspase-3 Proteins 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- 238000001516 cell proliferation assay Methods 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 201000009101 diabetic angiopathy Diseases 0.000 claims 1
- 201000002249 diabetic peripheral angiopathy Diseases 0.000 claims 1
- 230000002255 enzymatic effect Effects 0.000 claims 1
- 102000057928 human CAPN1 Human genes 0.000 claims 1
- 238000009396 hybridization Methods 0.000 claims 1
- 230000028709 inflammatory response Effects 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 208000019553 vascular disease Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 abstract 1
- 102100024654 Calcitonin gene-related peptide type 1 receptor Human genes 0.000 description 50
- 230000006870 function Effects 0.000 description 24
- 102000004379 Adrenomedullin Human genes 0.000 description 11
- 101800004616 Adrenomedullin Proteins 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- ULCUCJFASIJEOE-NPECTJMMSA-N adrenomedullin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H]1C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)NCC(=O)N[C@H](C(=O)N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)[C@@H](C)O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=CC=C1 ULCUCJFASIJEOE-NPECTJMMSA-N 0.000 description 10
- 108060003951 Immunoglobulin Proteins 0.000 description 9
- 102000018358 immunoglobulin Human genes 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 210000004897 n-terminal region Anatomy 0.000 description 8
- 101000584590 Homo sapiens Receptor activity-modifying protein 2 Proteins 0.000 description 6
- 102100030696 Receptor activity-modifying protein 2 Human genes 0.000 description 6
- 108090000932 Calcitonin Gene-Related Peptide Proteins 0.000 description 5
- 101000584583 Homo sapiens Receptor activity-modifying protein 1 Proteins 0.000 description 5
- 102100030697 Receptor activity-modifying protein 1 Human genes 0.000 description 5
- 102100030711 Receptor activity-modifying protein 3 Human genes 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 102100038518 Calcitonin Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 238000007792 addition Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 102000055006 Calcitonin Human genes 0.000 description 3
- 108060001064 Calcitonin Proteins 0.000 description 3
- 210000003719 b-lymphocyte Anatomy 0.000 description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 3
- 229960004015 calcitonin Drugs 0.000 description 3
- 239000013626 chemical specie Substances 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 229940124597 therapeutic agent Drugs 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108010078311 Calcitonin Gene-Related Peptide Receptors Proteins 0.000 description 2
- 102000036770 Islet Amyloid Polypeptide Human genes 0.000 description 2
- 108010041872 Islet Amyloid Polypeptide Proteins 0.000 description 2
- 102000041801 RAMP family Human genes 0.000 description 2
- 108091078765 RAMP family Proteins 0.000 description 2
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 102000008323 calcitonin gene-related peptide receptor activity proteins Human genes 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 210000002443 helper t lymphocyte Anatomy 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 229960005486 vaccine Drugs 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- -1 1 to 30 amino acids Chemical class 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 102000004414 Calcitonin Gene-Related Peptide Human genes 0.000 description 1
- 108010001789 Calcitonin Receptors Proteins 0.000 description 1
- 102100038520 Calcitonin receptor Human genes 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108091006027 G proteins Proteins 0.000 description 1
- 102000030782 GTP binding Human genes 0.000 description 1
- 108091000058 GTP-Binding Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
- 102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
- 108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108700022034 Opsonin Proteins Proteins 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102000019259 Succinate Dehydrogenase Human genes 0.000 description 1
- 108010012901 Succinate Dehydrogenase Proteins 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000012804 iterative process Methods 0.000 description 1
- 108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0521139.6A GB0521139D0 (en) | 2005-10-18 | 2005-10-18 | Therapeutic agent |
| PCT/GB2006/050338 WO2007045927A2 (en) | 2005-10-18 | 2006-10-18 | Therapeutic agent |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012190219A Division JP2012246309A (ja) | 2005-10-18 | 2012-08-30 | 治療薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009515827A true JP2009515827A (ja) | 2009-04-16 |
| JP2009515827A5 JP2009515827A5 (enExample) | 2011-06-02 |
Family
ID=35451928
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008536134A Pending JP2009515827A (ja) | 2005-10-18 | 2006-10-18 | 治療薬 |
| JP2012190219A Pending JP2012246309A (ja) | 2005-10-18 | 2012-08-30 | 治療薬 |
| JP2014193911A Pending JP2015003920A (ja) | 2005-10-18 | 2014-09-24 | 治療薬 |
| JP2015133603A Pending JP2015178534A (ja) | 2005-10-18 | 2015-07-02 | 治療薬 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012190219A Pending JP2012246309A (ja) | 2005-10-18 | 2012-08-30 | 治療薬 |
| JP2014193911A Pending JP2015003920A (ja) | 2005-10-18 | 2014-09-24 | 治療薬 |
| JP2015133603A Pending JP2015178534A (ja) | 2005-10-18 | 2015-07-02 | 治療薬 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US20080279857A1 (enExample) |
| EP (2) | EP2402372A3 (enExample) |
| JP (4) | JP2009515827A (enExample) |
| KR (1) | KR20080059449A (enExample) |
| CN (2) | CN101341171A (enExample) |
| AU (1) | AU2006305654B2 (enExample) |
| CA (1) | CA2624931A1 (enExample) |
| GB (1) | GB0521139D0 (enExample) |
| RU (1) | RU2008119096A (enExample) |
| WO (1) | WO2007045927A2 (enExample) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012255710A (ja) * | 2011-06-08 | 2012-12-27 | Pola Chem Ind Inc | スクリーニング方法 |
| JP2016124813A (ja) * | 2014-12-26 | 2016-07-11 | 国立大学法人広島大学 | 軟骨変性抑制剤および変形性関節症抑制剤 |
| JP2022512860A (ja) * | 2018-11-06 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物 |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030114410A1 (en) | 2000-08-08 | 2003-06-19 | Technion Research And Development Foundation Ltd. | Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis |
| GB0521139D0 (en) | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
| GB0708002D0 (en) * | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
| CN110372795A (zh) | 2007-08-02 | 2019-10-25 | 吉利德生物制剂公司 | Lox和loxl2抑制剂及其应用 |
| JP5099856B2 (ja) | 2007-11-26 | 2012-12-19 | 独立行政法人科学技術振興機構 | 代謝症候群の治療もしくは予防剤、検査方法、検査薬、及び代謝症候群の治療薬の候補化合物のスクリーニング方法 |
| FR2934597B1 (fr) * | 2008-07-31 | 2013-04-19 | Univ Aix Marseille Ii | Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament. |
| JO3382B1 (ar) | 2008-12-23 | 2019-03-13 | Amgen Inc | أجسام مضادة ترتبط مع مستقبل cgrp بشري |
| WO2010080769A2 (en) | 2009-01-06 | 2010-07-15 | Arresto Biosciences, Inc. | Chemotherapeutic methods and compositions |
| RU2012110585A (ru) | 2009-08-21 | 2013-09-27 | Джилид Байолоджикс, Инк. | Каталичические домены лизилоксидазы и loxl2 |
| RU2015108348A (ru) | 2010-02-04 | 2015-07-20 | Джилид Байолоджикс, Инк. | Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения |
| FR2964103B1 (fr) | 2010-08-30 | 2018-11-23 | Universite D'aix-Marseille | Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament |
| EP2589963A1 (en) | 2011-11-04 | 2013-05-08 | Université de Provence (Aix-Marseille 1) | Diagnostic and treatment of an androgen-independent prostate cancer |
| WO2016044224A1 (en) | 2014-09-15 | 2016-03-24 | Amgen Inc. | Bi-specific anti-cgrp receptor/pac1 receptor antigen binding proteins and uses thereof |
| JOP20200116A1 (ar) | 2015-04-24 | 2017-06-16 | Amgen Inc | طرق لعلاج أو الوقاية من الصداع النصفي |
| CN105420247B (zh) * | 2015-12-09 | 2018-09-07 | 浙江大学 | 水稻不定根控制基因crlr1的应用 |
| AU2017376400A1 (en) * | 2016-12-13 | 2019-06-20 | Novozymes A/S | Methods for treating inflammatory conditions of the lungs |
| CA3075867A1 (en) * | 2017-09-13 | 2019-03-21 | Gene Techno Science Co., Ltd. | Anti-ramp2 antibody |
| BR112020019882A2 (pt) | 2018-04-02 | 2021-01-05 | Amgen Inc. | Composições de erenumabe e seus usos |
| GB202303531D0 (en) * | 2023-03-10 | 2023-04-26 | Fusion Antibodies Plc | Antibodies and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050834A2 (en) * | 2002-11-27 | 2004-06-17 | Genpath Pharmaceuticals, Incorporated | GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3045153A1 (de) | 1980-11-29 | 1982-07-08 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung von blutgerinnungsfaktoren und danach hergestellte praeparation der faktoren ix und x |
| US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| WO1990005144A1 (en) | 1988-11-11 | 1990-05-17 | Medical Research Council | Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US6291158B1 (en) | 1989-05-16 | 2001-09-18 | Scripps Research Institute | Method for tapping the immunological repertoire |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2124967C (en) | 1991-12-17 | 2008-04-08 | Nils Lonberg | Transgenic non-human animals capable of producing heterologous antibodies |
| EP0656946B2 (en) | 1992-08-21 | 2010-03-31 | Vrije Universiteit Brussel | Immunoglobulins devoid of light chains |
| KR100272659B1 (ko) | 1997-06-28 | 2000-12-01 | 김영환 | 반도체 소자의 금속배선 선폭 측정방법 |
| US20030055231A1 (en) | 1998-10-28 | 2003-03-20 | Jian Ni | 12 human secreted proteins |
| EP1283881A2 (de) | 2000-05-26 | 2003-02-19 | Noxxon Pharma AG | Immobilisierte nukleinsäuren und verwendungen davon |
| GB0521139D0 (en) | 2005-10-18 | 2005-11-23 | Univ Sheffield | Therapeutic agent |
| GB0708002D0 (en) * | 2007-04-25 | 2007-06-06 | Univ Sheffield | Antibodies |
-
2005
- 2005-10-18 GB GBGB0521139.6A patent/GB0521139D0/en not_active Ceased
-
2006
- 2006-10-18 CN CNA2006800477847A patent/CN101341171A/zh active Pending
- 2006-10-18 CN CN201510206436.0A patent/CN105037551A/zh active Pending
- 2006-10-18 EP EP11162714A patent/EP2402372A3/en not_active Withdrawn
- 2006-10-18 WO PCT/GB2006/050338 patent/WO2007045927A2/en not_active Ceased
- 2006-10-18 US US12/090,635 patent/US20080279857A1/en not_active Abandoned
- 2006-10-18 CA CA002624931A patent/CA2624931A1/en not_active Abandoned
- 2006-10-18 KR KR1020087011686A patent/KR20080059449A/ko not_active Withdrawn
- 2006-10-18 AU AU2006305654A patent/AU2006305654B2/en not_active Ceased
- 2006-10-18 JP JP2008536134A patent/JP2009515827A/ja active Pending
- 2006-10-18 RU RU2008119096/13A patent/RU2008119096A/ru not_active Application Discontinuation
- 2006-10-18 EP EP06794995A patent/EP1945670A2/en not_active Withdrawn
-
2010
- 2010-08-03 US US12/849,536 patent/US8895005B2/en not_active Expired - Fee Related
-
2012
- 2012-08-30 JP JP2012190219A patent/JP2012246309A/ja active Pending
-
2014
- 2014-09-24 JP JP2014193911A patent/JP2015003920A/ja active Pending
- 2014-10-09 US US14/511,099 patent/US9556268B2/en not_active Expired - Fee Related
-
2015
- 2015-07-02 JP JP2015133603A patent/JP2015178534A/ja active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004050834A2 (en) * | 2002-11-27 | 2004-06-17 | Genpath Pharmaceuticals, Incorporated | GPC99 AND GPC99a: METHODS AND COMPOSITIONS FOR TREATING CANCER |
Non-Patent Citations (2)
| Title |
|---|
| JPN6012010079; Ｉｎｔ． Ｊ． Ｃａｎｃｅｒ Ｖｏｌ．１０８, 2004, ｐ．７９７-８０４ * |
| JPN6012010082; ＴＨＥ ＪＯＵＲＮＡＬ ＯＦ ＢＩＯＬＯＧＩＣＡＬ ＣＨＥＭＩＳＴＲＹ Ｖｏｌ．２７６， Ｎｏ．５２, 2001, ｐ．４９４５９-４９４６５ * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2012255710A (ja) * | 2011-06-08 | 2012-12-27 | Pola Chem Ind Inc | スクリーニング方法 |
| JP2016124813A (ja) * | 2014-12-26 | 2016-07-11 | 国立大学法人広島大学 | 軟骨変性抑制剤および変形性関節症抑制剤 |
| JP2022512860A (ja) * | 2018-11-06 | 2022-02-07 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 白血病幹細胞を根絶することによる急性骨髄性白血病の治療のための方法および医薬組成物 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20110195076A1 (en) | 2011-08-11 |
| AU2006305654B2 (en) | 2013-07-11 |
| JP2015003920A (ja) | 2015-01-08 |
| CN105037551A (zh) | 2015-11-11 |
| US8895005B2 (en) | 2014-11-25 |
| EP2402372A3 (en) | 2012-05-02 |
| CN101341171A (zh) | 2009-01-07 |
| GB0521139D0 (en) | 2005-11-23 |
| WO2007045927A2 (en) | 2007-04-26 |
| US20080279857A1 (en) | 2008-11-13 |
| US9556268B2 (en) | 2017-01-31 |
| AU2006305654A1 (en) | 2007-04-26 |
| CA2624931A1 (en) | 2007-04-26 |
| EP1945670A2 (en) | 2008-07-23 |
| EP2402372A2 (en) | 2012-01-04 |
| US20150037344A1 (en) | 2015-02-05 |
| JP2012246309A (ja) | 2012-12-13 |
| KR20080059449A (ko) | 2008-06-27 |
| WO2007045927A3 (en) | 2007-08-02 |
| JP2015178534A (ja) | 2015-10-08 |
| RU2008119096A (ru) | 2009-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2009515827A (ja) | 治療薬 | |
| TWI803523B (zh) | Ｔｉｇｉｔ抗體、其抗原結合片段及醫藥用途 | |
| TWI823895B (zh) | 抗b7-h4抗體、其抗原結合片段及其醫藥用途 | |
| JP7215759B2 (ja) | ４－１ｂｂ抗体およびその製造方法と使用 | |
| CN111902428B (zh) | 一种双特异性抗体及其用途 | |
| EP3307322A1 (en) | Humanized anti-cd40 antibodies and uses thereof | |
| KR20170070243A (ko) | 항-pd-1 항체 | |
| IL225484A (en) | Anti-48cd antibodies and their uses | |
| JP6900051B2 (ja) | Ｃｌａｕｄｉｎ ５抗体、及びその抗体を含有する医薬 | |
| JP2022547850A (ja) | 抗ｔｉｇｉｔ免疫阻害剤及び応用 | |
| JP2009515827A5 (enExample) | ||
| HK1250146A1 (zh) | 抗前-bcr拮抗剂和方法 | |
| WO2014139425A1 (zh) | 一种抗Blys的单克隆抗体及含有该抗体的药物组合物 | |
| CN113747917A (zh) | 针对MHC结合的人Dickkopf-1肽的单克隆抗体及其应用 | |
| CN113710321A (zh) | 用于治疗癌症的方法和组合物 | |
| CN114641307A (zh) | 抗cd19抗体及其用途 | |
| CN118146376B (zh) | Hla-g抗体及其制备方法和用途 | |
| KR20210005082A (ko) | 항-cd40 항체 및 이의 용도 | |
| US20200024347A1 (en) | Or10h1 antigen binding proteins and uses thereof | |
| US12331133B2 (en) | Therapeutic antibodies for treating lung cancer | |
| CN120623352A (zh) | 抗human IgG的抗体、其制备方法及用途 | |
| CN120665199A (zh) | 抗human IgG的抗体、其制备方法及用途 | |
| CN118184783A (zh) | Hla-g抗体及其制备方法和用途 | |
| JP5246859B2 (ja) | 抗体産生細胞の誘導又は活性化方法 | |
| CN120098124A (zh) | 一种抗bdca-2抗体及其制备方法和应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20090327 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20090327 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20091016 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20091016 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110404 |
|
| A524 | Written submission of copy of amendment under article 19 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A524 Effective date: 20110404 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120302 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20120516 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20120523 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121116 |